Molecularly targeted therapies for melanoma

Int J Dermatol. 2013 May;52(5):523-30. doi: 10.1111/j.1365-4632.2012.05829.x.

Abstract

Systemic and topical targeted therapies are emerging as a rational approach to the management of skin cancers. In this article, we review the molecular pathways critical to the development of melanoma and the novel pharmacologic agents that have been rationally designed to target it. Included is a review of vemurafenib, imatinib, and ipilimumab for metastatic or unresectable melanoma.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Benzamides / pharmacology
  • Benzamides / therapeutic use
  • Humans
  • Imatinib Mesylate
  • Immunotherapy
  • Indoles / pharmacology
  • Indoles / therapeutic use
  • Ipilimumab
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Mesylates / pharmacology
  • Mesylates / therapeutic use
  • Molecular Targeted Therapy*
  • Mutation
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf / genetics*
  • Proto-Oncogene Proteins B-raf / metabolism
  • Proto-Oncogene Proteins c-kit / genetics*
  • Proto-Oncogene Proteins c-kit / metabolism
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use
  • Vemurafenib

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Benzamides
  • Indoles
  • Ipilimumab
  • Mesylates
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Vemurafenib
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit
  • Proto-Oncogene Proteins B-raf